Xvivo Perfusion (XVIVO.ST) Stock Price
Xvivo Perfusion Price
Revenue has compounded at 21.3% per year over the past 14 years to 812.17 M SEK. Earnings per share have grown at 5.7% per year over the last 12 years. Xvivo Perfusion's net margin stands at 3.1%, broadly stable from 3.2% several years earlier. Analysts set a median price target of 306.00 SEK, implying 25.6% above the current price. Of 13 analysts, 12 rate the stock a buy — an overall Buy consensus. The stock trades about 51% above its 52-week low.
Xvivo Perfusion stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Xvivo Perfusion over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Xvivo Perfusion stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Xvivo Perfusion's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Xvivo Perfusion Price |
|---|---|
| 9/23/2026 | 243.60 SEK |
| 9/22/2026 | 237.80 SEK |
| 9/21/2026 | 244.60 SEK |
| 9/18/2026 | 247.80 SEK |
| 9/17/2026 | 245.00 SEK |
| 9/16/2026 | 248.40 SEK |
| 9/15/2026 | 250.60 SEK |
| 9/14/2026 | 254.00 SEK |
| 9/11/2026 | 250.40 SEK |
| 9/10/2026 | 258.00 SEK |
| 9/9/2026 | 259.40 SEK |
| 9/8/2026 | 262.60 SEK |
| 9/7/2026 | 263.00 SEK |
| 9/4/2026 | 259.80 SEK |
| 9/3/2026 | 264.20 SEK |
| 9/2/2026 | 261.00 SEK |
| 9/1/2026 | 261.80 SEK |
| 8/31/2026 | 263.60 SEK |
| 8/28/2026 | 272.20 SEK |
| 8/27/2026 | 284.40 SEK |
| 8/26/2026 | 281.00 SEK |
| 8/25/2026 | 278.80 SEK |
| 8/21/2026 | 280.00 SEK |
| 8/20/2026 | 276.00 SEK |
| 8/19/2026 | 280.00 SEK |
| 8/17/2026 | 282.00 SEK |
| 8/14/2026 | 295.20 SEK |
| 8/13/2026 | 309.00 SEK |
| 8/12/2026 | 308.40 SEK |
| 8/11/2026 | 305.00 SEK |
Xvivo Perfusion Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Xvivo Perfusion Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 0.14 | 0.15 | 0.19 | 0.22 | 0.18 | 0.26 | 0.42 | 0.60 | 0.82 | 0.81 | 0.99 | 1.26 | 1.61 | 2.19 | 2.79 |
| 42.86 | 15.00 | 7.25 | 26.35 | 17.65 | -18.64 | 44.13 | 60.85 | 43.86 | 37.69 | -1.22 | 21.92 | 26.87 | 28.42 | 35.90 | 27.42 |
| 70.00 | 73.91 | 76.35 | 72.19 | 73.64 | 73.74 | 72.87 | 71.33 | 74.54 | 74.94 | 65.64 | 65.64 | 65.64 | 65.64 | 65.64 | 65.64 |
| 0.08 | 0.10 | 0.11 | 0.14 | 0.16 | 0.13 | 0.19 | 0.30 | 0.45 | 0.62 | 0.53 | 0.65 | 0.82 | 1.06 | 1.44 | 1.83 |
| 7.00 | 2.00 | 7.00 | 14.00 | 5.00 | -56.00 | 6.00 | 23.00 | 9.00 | 88.00 | 93.00 | 129.00 | 232.00 | 360.00 | 562.00 | 881.00 |
| 5.83 | 1.45 | 4.73 | 7.49 | 2.27 | -31.28 | 2.33 | 5.54 | 1.51 | 10.71 | 11.45 | 13.03 | 18.47 | 22.32 | 25.64 | 31.54 |
| 5.00 | 1.00 | 6.00 | 12.00 | 4.00 | -43.00 | 8.00 | 18.00 | 91.00 | 172.00 | 25.00 | 110.00 | 192.00 | 301.00 | 469.00 | 745.00 |
| 66.67 | -80.00 | 500.00 | 100.00 | -66.67 | -1,175.00 | -118.60 | 125.00 | 405.56 | 89.01 | -85.47 | 340.00 | 74.55 | 56.77 | 55.81 | 58.85 |
| 21.51 | 23.61 | 26.19 | 26.40 | 26.60 | 28.60 | 29.40 | 29.60 | 31.50 | 31.65 | 31.56 | 31.56 | 31.56 | 31.56 | 31.56 | 31.56 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Xvivo Perfusion generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Xvivo Perfusion retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Xvivo Perfusion's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Xvivo Perfusion has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Xvivo Perfusion's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Xvivo Perfusion stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Xvivo Perfusion Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Xvivo Perfusion business model & stock analysis
Xvivo Perfusion SWOT Analysis
Strengths
Xvivo Perfusion AB has several strengths that contribute to its success and competitive advantage. Firstly, the company possesses advanced technologies and expertise in organ and lung perfusion systems, allowing them to effectively address the growing demand for organ transplantation. Secondly, Xvivo Perfusion AB has a strong global presence and a well-established network of distribution channels, enabling them to reach international markets efficiently. Lastly, the company has a talented and dedicated workforce, which plays a crucial role in driving innovation and maintaining superior product quality.
Weaknesses
Despite its strengths, Xvivo Perfusion AB also faces certain weaknesses that need to be addressed. One notable weakness is the company's reliance on a limited number of key customers, potentially exposing them to financial risks if these customers choose to seek alternative suppliers. Additionally, Xvivo Perfusion AB may face challenges in securing regulatory approvals for their products in certain markets, which can hinder their ability to expand globally. Lastly, the company could benefit from enhancing their marketing efforts to further increase brand awareness and capture larger market share.
Opportunities
There are several opportunities available for Xvivo Perfusion AB to capitalize on. Firstly, the growing demand for organ transplantation presents a significant market opportunity for the company to expand its customer base and increase sales. Secondly, advancements in medical research and technology provide an opportunity for Xvivo Perfusion AB to develop and introduce innovative perfusion systems with improved functionalities, setting them apart from competitors. Lastly, strategic partnerships and collaborations with hospitals, research institutions, and pharmaceutical companies can provide access to complementary expertise and resources, fostering innovation and driving market growth.
Threats
Xvivo Perfusion AB faces several threats that could impact its business. Firstly, intense competition within the medical technology industry poses a threat, as other companies with similar perfusion solutions may attempt to gain market share. Additionally, regulatory changes and stringent approval processes in certain countries can hinder Xvivo Perfusion AB's ability to enter new markets or cause delays in product launches. Furthermore, economic downturns or financial instability in key markets can impact customer demand for organ and lung perfusion systems. Lastly, disruptive technologies or breakthroughs in alternative transplantation methods could pose a long-term threat if Xvivo Perfusion AB fails to adapt and evolve its offerings accordingly.
Xvivo Perfusion Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Xvivo Perfusion historical P/E ratio, EBIT multiple, and P/S ratio
Xvivo Perfusion annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Xvivo Perfusion's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Xvivo Perfusion's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Xvivo Perfusion's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Xvivo Perfusion shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Xvivo Perfusion forecasts and price targets in September 2026
Analyst Price Targets 2026Xvivo Perfusion Earnings Calls
Xvivo Perfusion Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 10/22/2026 | 0.80SEK | - | 237.57 MSEK | - | 2026 Q3 |
| 7/14/2026 | 0.75SEK | 0.65SEK | 235.75 MSEK | - | 2026 Q2 |
| 4/24/2026 | 0.94SEK | 1.15SEK | 235.87 MSEK | - | 2026 Q1 |
| 1/27/2026 | 0.68SEK | 1.05SEK | 214.07 MSEK | - | 2025 Q4 |
| 10/23/2025 | 0.44SEK | 0.26SEK | 214.07 MSEK | - | 2025 Q3 |
| 7/11/2025 | 0.62SEK | 0.05SEK | 218.12 MSEK | - | 2025 Q2 |
| 4/24/2025 | 0.79SEK | -0.40SEK | 210.58 MSEK | - | 2025 Q1 |
| 1/28/2025 | 0.77SEK | 1.16SEK | 211.67 MSEK | - | 2024 Q4 |
| 10/24/2024 | 0.68SEK | 2.71SEK | 205.77 MSEK | - | 2024 Q3 |
| 7/12/2024 | 0.64SEK | 0.86SEK | 193.70 MSEK | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Xvivo Perfusion stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Xvivo Perfusion shareholder structure
| % | Name |
|---|---|
3.59346% | |
2.46871% | |
1.47352% | |
1.39430% | |
0.86750% | |
0.85188% |
Xvivo Perfusion Beneficial Ownership Filings (SEC 13D/G)
Xvivo Perfusion Executives and Management Board
15 members · avg. age 56 · 33 % women
Mr. Christoffer Rosenblad (50)
Chief Executive Officer
782,000.00 SEK
Management
Ms. Lena Hagman (60)
Deputy Chief Executive Officer, Chief Operating Officer
Mr. Kristoffer Nordstroem (40)
Chief Financial Officer
Ms. Ylva Vihoj (55)
Senior Vice President of Human Resources
Mr. Johan Holmstroem (55)
Senior Vice President, Commercial Europe & RoW · since 2024
Mr. Mark Reade
Senior Vice President, North America
Ms. Jaya Tiwari (38)
Senior Vice President, Clinical & Regulatory Affairs, North America
Board of Directors
Mr. Gosta Johannesson (66)
Chairman of the Board
Ms. Camilla Oberg (61)
Independent Director
Mr. Goeran Dellgren (64)
Independent Director
Mr. Lars Henriksson (70)
Independent Director
Ms. Lena Hoeglund (65)
Independent Director
Mr. Paul Marcun (59)
Independent Director
Xvivo Perfusion Supply Chain
Xvivo Perfusion Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.60 | 0.70 | 0.75 | ||
| 2 | Swedbank A | 0.32 | 0.20 | 0.43 |
Frequently asked questions about Xvivo Perfusion
Xvivo Perfusion AB specializes in providing innovative solutions for organ transplantation and advanced organ preservation. Their business model revolves around developing and commercializing state-of-the-art medical technology and systems that enable better organ transportation and preservation. Xvivo Perfusion AB offers products like the XPS™ (Xvivo Perfusion System), which enables safe evaluation and preservation of donor organs, and STEEN Solution™, a cold perfusion system used for lung preservation. By focusing on improving transplantation outcomes and extending organ viability, Xvivo Perfusion AB plays a crucial role in the organ transplantation field.
Xvivo Perfusion AB is primarily active in the healthcare and medical device industries.
The main competitors of Xvivo Perfusion AB in the market include Organ Recovery Systems, XVIVO Surgical AB, TransMedics Group Inc., and OrganOx Limited.
Xvivo Perfusion AB is a renowned medical technology company specializing in solutions for organ transplantation. Established in 1998, Xvivo Perfusion has been a trusted name in the industry. The company focuses on developing advanced systems and solutions for organ preservation and evaluation prior to transplantation, ensuring optimal outcomes for patients and healthcare professionals alike. With its innovative technology and dedication to improving transplantation processes, Xvivo Perfusion has gained significant recognition globally. This Swedish-based company continues to play a vital role in advancing organ transplantation practices and contributing to enhanced patient care worldwide.
Some significant milestones achieved by Xvivo Perfusion AB include the development and commercialization of the XPS system, a medical device used for ex-vivo perfusion of organs. The company successfully received clearance from the FDA in 2014 to market the XPS system in the United States, significantly expanding its reach. In 2016, Xvivo Perfusion achieved another milestone by conducting the first-ever transplantation of human lungs, which were perfused and evaluated using their XPS system. These achievements demonstrate the company's expertise in the field of organ preservation and transplantation, positioning Xvivo Perfusion AB as a key player in advancing medical technologies for organ transplant procedures.
Xvivo Perfusion AB is primarily present in several countries and regions around the world. With a global presence, the company operates in Europe, North America, Latin America, and Asia-Pacific. Its reach extends to countries such as Sweden, the United States, Germany, France, the United Kingdom, Canada, Brazil, Australia, and many more. Xvivo Perfusion AB has established a strong international footprint, allowing it to cater to a diverse range of markets and provide its innovative perfusion solutions to healthcare professionals worldwide.
Xvivo Perfusion AB is a medical technology company that specializes in providing solutions for organ transplantation and preservation. The company's values revolve around innovation, patient focus, and quality. Xvivo Perfusion AB's corporate philosophy is centered on improving patient outcomes by developing and commercializing advanced products and services that ensure the safe and effective transport and preservation of organs. With a strong commitment to excellence and continuous improvement, Xvivo Perfusion AB strives to be a leader in the field of organ transplantation, contributing to the advancement of medical science and ultimately saving lives.
Analysts currently set an average price target of 312.12 SEK for the Xvivo Perfusion stock (median: 306.00 SEK), implying +31.3 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Xvivo Perfusion stock: 12 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Xvivo Perfusion to generate revenue of 990.90 M SEK and earnings per share of 3.51 SEK.
Converted at the current exchange rate, the Xvivo Perfusion share trades at 21.63 EUR (243.60 SEK).
The Xvivo Perfusion share (XVIVO.ST) is listed on 7 stock exchanges, including: London (0RKL.L), Frankfurt (3XV.F), München (3XV.MU), Stockholm (XVIVO.ST).
Xvivo Perfusion AB is a leading company in the development and manufacturing of products for organ perfusion that save lives. The company was founded in 1998 in Gothenburg, Sweden and employs over 230 employees worldwide. The company's business model is based on the production and marketing of clinical perfusion products for transplantation. The product range includes, among others, the XPS (Xvivo Perfusion System), a system for machine perfusion preparation and support of organs before transplantation. The company is particularly strong in the field of lung and liver perfusion and has brought several successful products to the market in this area. One of the new products is the Perfusix, a machine for the preparation of lungs that allows the use of organs from different sources and their evaluation before transplantation. The company is highly respected by customers due to its excellent performance and high product quality. Xvivo Perfusion AB follows a vertical business approach, fulfilling the needs of its customers through the development and production of clinical products for organ preparation. The customers are mainly transplant clinics that use the XPS to improve organ quality and increase patient survival rates. In addition, Xvivo Perfusion AB offers excellent training and consulting services to help customers maximize the full potential of their products. This extends the lifespan of the products and enables the market entry of new products. The company also has a strong commitment to research and development. They have partnerships with leading research institutes around the world to further enhance the performance of their products. This collaboration also provides an opportunity to develop new products and expand into other application areas. Overall, the business model of Xvivo Perfusion AB is very solid and tailored to the needs of customers. Through the development of new products and collaboration with research and development partners, the company is well positioned to expand its performance offering and meet the needs of customers.
The expected revenue of Xvivo Perfusion is 990.90 M SEK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Xvivo Perfusion is 110.89 M SEK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Xvivo Perfusion is currently 69.32. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Xvivo Perfusion stock.
The price-to-sales ratio (P/S) of Xvivo Perfusion is currently 7.76. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Xvivo Perfusion stock.
The Eulerpool Quality Score for Xvivo Perfusion is 6/10.
The ISIN of Xvivo Perfusion is SE0004840718. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Xvivo Perfusion is A1J5GZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Xvivo Perfusion is XVIVO.ST. The ticker symbol is used to trade Xvivo Perfusion shares on the stock exchange.
Xvivo Perfusion paid dividends every year for the past 0 years.
Xvivo Perfusion is assigned to the 'Health' sector.
The dividends of Xvivo Perfusion are distributed in SEK.
Xvivo Perfusion stock
Xvivo Perfusion Peer Group
Xvivo Perfusion Ticker
Xvivo Perfusion FIGI
All fundamentals and in-depth analysis of Xvivo Perfusion
Our stock analysis for Xvivo Perfusion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Xvivo Perfusion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.